
{"publication_number": "US-2002045664-A1", "abstract": "a method for treating symptoms , diseases and conditions in extra - reproductive tract tissues that are responsive to treatment with estrogen , using triarylethanes of formula wherein r 1 is \u2014 o m r 3 or \u2014 n r 3 ; wherein r 3 is an anionic substituent ; m is an integer from 1 to 4 ; and n is an integer from 0 to 4 ; and wherein r 2 is either h or \u2014 oh . each of r 1 and r 2 can be either meta or para to its respective phenyl ethyl linkage . compounds having the formula wherein r 1 is \u2014 o m r 3 or \u2014 n r 3 ; r 3 is an anionic substituent ; m is 1 , 2 , 3 or 4 ; n is 0 , 1 , 2 , 3 or 4 ; r 2 is h or \u2014 oh ; and wherein each of r 1 and r 2 is independently meta or para to its respective phenyl ethyl linkage are also provided , with the proviso that r 2 is not para \u2014 oh when m is 1 and r 3 is \u2014 cooh .", "application_number": "US-98161701-A", "description": "abbreviations . the following abbreviations are used throughout the specification : er , estrogen receptor ; ert , estrogen replacement therapy ; ovx , ovariectomized ; tam , tamoxifen (( z )- 2 -[ 4 -( 1 , 2 - diphenyl - 1 - butenyl ) phenoxy ]- n , n - dimethylethanamine ); clo , clomiphene ( 2 -[ 4 -( 2 - chloro - 1 , 2 - diphenylethenyl ) phenoxy ]- n , n - diethylethanamine ); 4 - hydroxy clo , 4 - hydroxyclomiphene ( 4 -[ 1 -( p - hydroxyphenyl )- 2 - phenyl - 2 - chloroethenyl ] phenoxyethyl - n , n - diethylamine ); 4hta , 4 - hydroxytamoxifen acid (( e , z )- 2 -{ 4 -[ 1 -( p - hydroxyphenyl )- 2 - phenyl ]- 1 - butenyl 